Top Markets
Coin of the day
TCR2 Therapeutics Inc. TCR2 Therapeutics Inc.

TCR2 Therapeutics Inc.

TCRR
Hisse Senetlerindeki Sıralama #27038
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on... TCR2 Therapeutics Inc. is a clinical-stage immunotherapy firm focused on developing cutting-edge T cell receptor (TCR) therapies for cancer patients. The company's lead investigational treatment, gavo-cel, is a unique mono TCR Fusion Construct T cell (TRuC-T cell) designed to target mesothelin-positive solid tumors. This therapy is currently being evaluated in Phase I/II clinical trials for non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma, and cholangiocarcinoma. Furthermore, TCR2 Therapeutics has concluded preclinical development for TC-510, another TRuC-T cell specifically engineered to target mesothelin on solid tumors. They are also advancing TC-520, a CD70-targeting TRuC-T cell designed with fratricide resistance for treating renal cell carcinoma. Founded in 2015, the company, formerly known as TCR2, Inc. until its name change in November 2016, is headquartered in Cambridge, Massachusetts.
Hisse Fiyatı
$1.48
Son senkronizasyon: 2023-05-31
Piyasa Değeri
$35.54M
Değişim (1 gün)
-5.73%
Değişim (1 yıl)
0.00%
Ülke
US
Ticaret TCR2 Therapeutics Inc. (TCRR)

Kategori

TCR2 Therapeutics Inc. (TCRR) için hisse senedi fiyat geçmişi
Gün sonu en yüksek fiyat: $1.83 - 2023-05-01

Gün sonu en düşük fiyat: $16.51 - 2019-02-01
TCR2 Therapeutics Inc. için hisse fiyatı geçmişi: 2019 - 2026
Yıllık Hisse Fiyatı Performansı
Yıl Performans
2023 73.43%
2022 -78.52%
2021 -83.60%
2020 79.84%
2019 0.00%
Benzer şirketler veya rakiplerin hisse fiyatı
Şirket Hisse fiyatı Değişim 1yıl% Ülke
$552.07 39.99%
US
$168.77 527.63%
US
$1.03K 56.22%
NL
$120.74 -14.98%
AU
$758.23 6.53%
CH